EAP
AKBA icon

Elevation Advisory Partners’s Akebia Therapeutics AKBA Stock Holding History

Elevation Advisory Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-120,000
Closed -$181K – 51
2026
Q1 		$181K Buy
+120,000
New +$165K 0.17% 95

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Elevation Advisory Partners's AKBA Position: Q2 2026 in Review

Elevation Advisory Partners sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 120,000 shares — an estimated $181K sold.

Elevation Advisory Partners first reported a position in AKBA in Q1 2026 and held it in 1 quarter. The position peaked at $181K in Q1 2026. 169 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Elevation Advisory Partners reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Elevation Advisory Partners sold 120,000 Akebia Therapeutics shares in Q2 2026, an estimated $181K.
  • Elevation Advisory Partners first reported a position in Akebia Therapeutics in Q1 2026 and held it in 1 quarter.
  • Elevation Advisory Partners's Akebia Therapeutics position peaked at $181K in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Elevation Advisory Partners's 13F filing for Q2 2026, filed 13 Aug 2026.